The Experts below are selected from a list of 405 Experts worldwide ranked by ideXlab platform

Pierre Youinou - One of the best experts on this subject based on the ideXlab platform.

  • Outcome of early monoarthritis: a followup study.
    The Journal of rheumatology, 2007
    Co-Authors: Aymeric Binard, Jean-marie Berthelot, Valérie Devauchelle-pensec, Seydou Alassane, Sandrine Jousse-joulin, Gérard Chalès, Catherine Le Henaff, Jean B Thorel, Sylvie Hoang, Pierre Youinou
    Abstract:

    OBJECTIVE: To evaluate clinical, laboratory, and radiological features and outcomes in patients with monoarthritis (MA), identified in a cohort of patients with early arthritis. METHODS: A cohort of 270 patients with undiagnosed arthritis of less than 1 year9s duration was divided into 3 groups: single episode of MA (MA, n = 27), MA with a history of patient-reported arthritis (MA + past, n = 23), and oligo- or polyarthritis (OA/PA, n = 220). At 6-month intervals, all patients underwent a standardized examination, radiographs, and standard laboratory tests including rheumatoid Factors (RF), Antiperinuclear Factor (APF), antikeratin antibody (AKA), anticyclic citrullinated peptide antibody (anti-CCP), antinuclear antibodies, and HLA-AB-DR typing. After a median followup of 30 months, the diagnosis was evaluated by a hospital-based rheumatologist. RESULTS: Age and sex did not differ across the 3 groups. Knee involvement was more common in the MA group than in the MA + past group (p

  • Antiperinuclear Factor and antikeratin/antifilaggrin antibodies for differentiating early rheumatoid arthritis from polymyalgia rheumatica
    Joint Bone Spine, 2001
    Co-Authors: Valérie Devauchelle-pensec, Pierre Youinou, Alain Saraux, Paul Le Goff
    Abstract:

    Abstract Objectives. To determine the prevalence and meaning of the Antiperinuclear Factor (APF) and antikeratin antibodies (AKA) in a group of patients with polymyalgia rheumatica (PMR) and/or giant cell arteritis (GCA) and to evaluate the usefulness of APF and AKA in distinguishing early rheumatoid arthritis (RA) from PMR/GCA in everyday clinical practice. Methods. Eighty patients with PMR and/or GCA were compared with 44 patients older than 50 years and admitted during the same period for evaluation of a possible diagnosis of RA. All the patients underwent a standardized evaluation including a physical examination and diagnostic investigations. Follow-up was 2 years. Results. Fourteen (17.5%) patients in the PMR/GCA group had APF in titers ⩾1/80, but only six (7.5%) had titers > 1/80. No significant differences were found between the subgroups with and without APF. None of these patients had detectable AKA. As compared to rheumatoid Factors (RF), APF and AKA showed poorer performances (sensitivity, 60%; specificity, 91%; efficiency, 77%) for diagnosing RA versus PMR/GCA. Combining RF and APF resulted in increased specificity (96%). Conclusions. The prevalence of APF in titers ⩾ 1/80 was high in PMR/GCA, but few patients (7.5%) had titers > 1/80. Presence of APF was not associated with specific features. All these patients were negative for AKA. RF has the best performance characteristics for diagnosing RA in older patients; RF combined with APF was more specific than RF alone.

  • Risk Factors for radiographic articular destruction of hands and wrists in rheumatoid arthritis.
    The Journal of rheumatology, 1999
    Co-Authors: H. Belghomari, Pierre Youinou, Alain Saraux, J. Allain, C. Guedes, P. Le Goff
    Abstract:

    Objective. To carry out a cross sectional case-control study of the risk Factors for articular destruction in a large sample of patients with a long history of rheumatoid arthritis (RA). presupposing that the variables we measured were unrelated to the duration of disease. Methods. Each inpatient with RA admitted to our department from January 1, 1985, to December 31, 1995, underwent standard examination, laboratory tests, and hand roentgenograms. We carried out a radiographic cross sectional study on 287 of them. Radiographic evaluation was performed by the same observer (correlation coefficient 0.97) using the modified Sharp method. To investigate an association between articular destruction and prognostic variables, a matched analysis of the case-control data and calculation of the odds ratio (OR) with 95% confidence intervals (CI) were carried out. For each patient with severe articular destruction, patients hospitalized during the study period with the same disease duration but without severe articular destruction were included as controls. The sample size was chosen to show an OR > 2 (1 - alpha = 95%; 1 - beta = 80%). Results. The risk of articular joint destruction was higher in women than in men (OR 2.72, Cl 1.17-7.9, p < 0.023). whereas age at onset or the presence of HLA-DR4, Antiperinuclear Factor, or antikeratin antibodies was not sufficiently strongly associated with the process of articular destruction to be considered relevant prognostic markers. Conclusion. We conclude that female sex is significantly associated with a higher risk of articular destruction.

  • Antiperinuclear Factor – clinical, serological and genetic correlates in Israeli patients with rheumatoid arthritis
    Rheumatology international, 1997
    Co-Authors: M. Tishler, Pierre Youinou, R. Maran, Pnina Langevitz, Avi Livneh, Ephraim Gazit, Boris Gilburd, Yehuda Shoenfeld
    Abstract:

    The possible association between the presence of Antiperinuclear Factor (APF) and clinical and genetic parameters was investigated in 54 Israeli patients with rheumatoid arthritis (RA). Rheumatoid Factor (RF) was detected in the sera of 43 patients (80%) and APF was positive in 33 (61%). No significant statistical differences were found in the presence of HLA-DR4 and/or DR1 between APF-positive and -negative patients. Furthermore, neither the Ritchie articular index nor the patient's functional class correlated with the presence of APF. The results of our study suggested that although Israeli patients have a different genetic background, the presence and behaviour of APF is similar to that of other Caucasian populations.

  • Perinuclear Factor (Profilaggrin) Autoantibodies
    Autoantibodies, 1996
    Co-Authors: Pierre Youinou, Paul Le Goff, R. Maran
    Abstract:

    Publisher Summary This chapter provides an overview of methods for detecting Antiperinuclear Factor (APF) antibodies and characterizes antigenic and biological properties of these antibodies. APF binds to cytoplasmic aggregates encircling the nucleus of buccal epithelial cells and termed “keratohyalin granules,” on the basis of their rough resemblance to the keratohyalin bodies in the stratum granulosum of human epidermis. The chapter states that Epstein-Barr virus infection, APF production by the patients, and perinuclear antigen (PNA) expression by the cell donors, are related by serum APF in over half of the patients with infectious mononucleosis. With the simple indirect immunofluorescence assay, the prevalence of the autoantibody has been evaluated in RA and other connective tissue diseases.

O. Meyer - One of the best experts on this subject based on the ideXlab platform.

  • British Journal of Rheumatology 1996;35:62O-624 DIAGNOSTIC VALUE OF ANTI-RA33 ANTIBODY, ANTTKERATIN ANTIBODY, ANTTPERINUCLEAR Factor AND ANTINUCLEAR ANTIBODY IN EARLY RHEUMATOID ARTHRITIS: COMPARISON WITH RHEUMATOID Factor
    2015
    Co-Authors: C. Cordonnier, O. Meyer, E. Palazzo, M. De Bandt, A. Elias, P. Nicaise, T. Halm, M. F. Kahn, G. Chatellier
    Abstract:

    The goal of this prospective longitudinal study was to determine the serological profile of early rheumatoid arthritis (RA), and to test whether antikeratin antibody (AKA), Antiperinuclear Factor (API7), anti-RA33 antibody and antinuclear antibodies (ANA) had an additional diagnostic value when prescribed after rheumatoid Factor (RF)-detecting methods. Sixty-nine patients with early polyarthritis suggestive of RA, seen between 1991 and 1993, were included. Five autoantibodies (i.e. RF, AKA, APF, RA33, ANA) were looked for at regular intervals. After 24 months follow-up, patients were classified as having RA (n = 49), unclassified polyarthritis (UP; n = 15) or other rheumatic diseases. Among patients with early RA, the sensitivity of these marker

  • Autoantibodies predicting the outcome of rheumatoid arthritis: evaluation in two subsets of patients according to severity of radiographic damage
    Annals of the rheumatic diseases, 1997
    Co-Authors: O. Meyer, A. Elias, Bernard Combe, K Benali, J Clot, Jacques Sany, Jean-françois Eliaou
    Abstract:

    OBJECTIVE Autoantibodies such as rheumatoid Factor (RF), antikeratin antibodies (AKA), Antiperinuclear Factor (APF), and anti-RA 33 antibodies are considered of value for the diagnosis of RA. The purpose of this study was to evaluate these autoantibodies as predictors of severe radiographic damage in rheumatoid arthritis (RA). PATIENTS AND METHODS Eighty six patients with RA (70 women, 16 men) fulfilling 1987 ACR criteria were selected from a cohort of 469 patients followed up since the first year of RA onset because they could be divided in two groups according to the severity of the radiographic damage. These 86 patients had a mean (SD) disease duration of eight (four) years: 43 patients had severe radiographic damage (Larsen score ⩾2) and 43 had limited radiographic damage (Larsen score RESULTS Patients with severe radiographic damage differed from those with limited radiographic damage in that they had higher RF (p=0.01), APF (p CONCLUSION These data suggest that the risk of severe radiographic damage in RA patients is higher when cutaneous nodules, HLA DRB1*04 or DRB1*01, and/or AKA are present. The other autoantibodies of diagnostic significance are of little help for predicting joint destruction.

  • DIAGNOSTIC VALUE OF ANTI-RA33 ANTIBODY, ANTIKERATIN ANTIBODY, Antiperinuclear Factor AND ANTINUCLEAR ANTIBODY IN EARLY RHEUMATOID ARTHRITIS: COMPARISON WITH RHEUMATOID Factor
    British journal of rheumatology, 1996
    Co-Authors: C. Cordonnier, O. Meyer, E. Palazzo, M. De Bandt, A. Elias, Nicaise P, T. Haim, G. Chatellier
    Abstract:

    The goal of this prospective longitudinal study was to determine the serological profile of early rheumatoid arthritis (RA), and to test whether antikeratin antibody (AKA), Antiperinuclear Factor (APF), anti-RA33 antibody and antinuclear antibodies (ANA) had an additional diagnostic value when prescribed after rheumatoid Factor (RF)-detecting methods. Sixty-nine patients with early polyarthritis suggestive of RA, seen between 1991 and 1993, were included. Five autoantibodies (i.e. RF, AKA, APF, RA33, ANA) were looked for at regular intervals. After 24 months follow-up, patients were classified as having RA (n = 49), unclassified polyarthritis (UP; n = 15) or other rheumatic diseases. Among patients with early RA, the sensitivity of these markers was 40.8% for RF, 36.7% for AKA, 28.6% for APF and 28.6% for anti-RA33. Among RF-negative RA patients, 51.7% were positive for AKA, APF, anti-RA33 antibodies and/or ANA. Positivity of the three recent markers usually persisted throughout follow-up, whereas RF was lost by 58% of patients with early, RF-positive, treated RA. Using multivariate analysis, only latex, RF test and AKA or APF had an independent and statistically significant diagnostic value for early RA. Our data suggest that RF and AKA (or APF) should be concomitantly determined for diagnosis in patients with suspected early RA.

  • Occurrence of Antiperinuclear, antikeratin, and anti-RA 33 antibodies in juvenile chronic arthritis.
    Annals of the rheumatic diseases, 1993
    Co-Authors: C Gabay, A M Prieur, O. Meyer
    Abstract:

    OBJECTIVES--Antiperinuclear Factor (APF), antikeratin antibodies (AKA), and anti-RA 33 antibodies are currently considered to be good markers for the diagnosis of adult rheumatoid arthritis with or without rheumatoid Factor (RF). The prevalence of these markers was retrospectively reviewed in children with juvenile chronic arthritis (JCA) to determine whether they were associated with specific features. METHODS--One hundred and twenty-four patients with JCA participated in this study. Controls included 28 patients with juvenile systemic lupus erythematosus and 21 healthy children. Antiperinuclear Factor and AKA were determined by indirect immunofluorescence on buccal mucosal cells and oesophagus sections respectively. Anti-RA 33 antibodies were detected using a Western blot technique on HeLa cell nuclear extract. RESULTS--Antiperinuclear Factor was virtually absent in all the tested subgroups and anti-RA 33 antibodies were detected only in a subset of patients with RF positive polyarticular onset. Antikeratin antibodies were found in 27% of all children with JCA and in 42% of those with RF negative polyarticular onset. These results were statistically significant compared with healthy controls, but the presence of AKA was not specific to any patient subgroup. Moreover, in contrast with previous studies in adult RA, no relation was found between the presence of AKA and disease severity or activity. CONCLUSION--These data suggest that APF, AKA, and anti-RA 33 antibodies are not useful for the diagnosis or classification of JCA.

Kimmo Aho - One of the best experts on this subject based on the ideXlab platform.

  • Antifilaggrin antibodies in recent-onset arthritis.
    Scandinavian journal of rheumatology, 1999
    Co-Authors: Kimmo Aho, Pekka Kurki, T. Palosuo, M Lukka, Heikki Isomäki, Hannu Kautiainen, Von Essen R
    Abstract:

    We evaluated the sensitivity and prognostic value of an enzyme-linked immunosorbent assay (ELISA) for the measurement of antifilaggrin antibodies (AFA), using filaggrin purified from human skin as an antigen. The AFA test was applied to a series of 306 patients with various recent-onset inflammatory joint diseases. The results were compared to those of the conventional immunofluorescence tests for antikeratin antibody (AKA) and Antiperinuclear Factor (APF) and of the rheumatoid Factor (RF) tests from a previous study. There was a very good agreement between the results of the tests for APF and AFA (kappa-value 0.79 in patients with peripheral poly/oligoarthritis). The agreement between the tests for AKA and AFA was significant but less pronounced (kappa-value 0.50). The AFA test detected 10/22 of the RF-negative erosive cases, particularly those with a large number of erosive joints. Thus, the test for AFA supplements RF in the prediction of erosiveness.

  • Antibody to Stratum Corneum (Antikeratin Antibody) and Antiperinuclear Factor: Markers for Progressive Rheumatoid Arthritis
    Scandinavian journal of rheumatology, 1997
    Co-Authors: Pekka Kurki, R. Von Essen, T. Palosuo, K. Kaarela, Heikki Isomäki, Kimmo Aho
    Abstract:

    The purpose of this study was to examine the relationship between circulating antibodies to stratum corneum (AKA) and Antiperinuclear Factors (APF) on one hand, and the x-ray progression of joint damage in chronic poly/oligoarthritis on the other hand.The analysis involved 133 patients with either rheumatoid or nonspecific arthritis derived from a cohort of 442 patients with recent onset arthritis. The patients were followed up for eight years with regular clinical, laboratory, and radiological evaluations. Radiographic evidence of joint destruction was quantitated by a radiographic index based on the Larsen grading.AKA and APF were detected, either at entry or at follow-up, in 26 and 54 patients, respectively. Seventy-six of the 133 patients had developed erosions. All AKA-positive patients had a rheumatoid Factor-positive erosive poly-arthritis. The presence of APF was also associated with a progressive arthritis although four APF-positive patients had a non-erosive disease. Neither AKA nor APF were abl...

  • Marker antibodies of rheumatoid arthritis: Diagnostic and pathogenetic implications
    Seminars in arthritis and rheumatism, 1994
    Co-Authors: Kimmo Aho, Timo Palosuo, Pekka Kurki
    Abstract:

    Rheumatoid arthritis (RA) is associated with several autoantibodies specific enough to serve as diagnostic and prognostic markers. These include rheumatoid Factor (RF), antikeratin antibody (AKA), Antiperinuclear Factor (APF), and anti-RA33. The first three, and possibly also anti-RA33, may precede the onset of clinical RA. The prevalence of positive test reactions depends on the period between taking the specimen and onset of disease; when the period is short, the prevalence is nearly the same as in established disease. Thus, RA has a long asymptomatic period with broadening immunological activity. The assays for AKA and APF (and possibly also for anti-RA33), compared with RF testing, yielded greater specificity rather than the ability to define any subgroup with particularly severe disease. Used together, the above marker antibodies may form a new and more enlightened basis for defining seropositive RA. It is commonly believed that genetically mediated immune response plays an important role in the initiation of RA. However, the role of the major histocompatibility complex antigens may be in modulation of the inflammatory reaction in a later phase.

  • Antikeratin antibody and Antiperinuclear Factor as markers for subclinical rheumatoid disease process
    The Journal of rheumatology, 1993
    Co-Authors: Kimmo Aho, R. Von Essen, Pekka Kurki, T. Palosuo, Markku Heliövaara
    Abstract:

    OBJECTIVE Antikeratin antibody (AKA) and Antiperinuclear Factor (APF) are antibodies characteristic for rheumatoid arthritis (RA). Our purpose was to obtain information on the occurrence of APF before the onset of clinical disease and on the occurrence of AKA and APF in cases with false-positive rheumatoid Factor (RF) reactions. METHODS AKA and APF were measured with indirect immunofluorescence technique using rat esophagus and buccal mucosa cells, respectively, as antigen source. RESULTS Five of 30 preillness specimens from subjects who later developed seropositive RA were positive for AKA and APF, 3 sera were positive for only AKA and 3 for only APF. All the eleven sera positive for AKA or APF were RF positive. Both AKA and APF were detected in 6 of 70 sera from RF positive subjects who did not develop RA within a 10-year followup, 3 sera were positive for only AKA and 3 for only APF. CONCLUSION AKA and APF appear to be linked markers of an immunological process which, in RF positive subjects, predicts the development of clinical arthritis. However, disease manifestations develop in only a proportion of cases.

  • Prospect for an Additional Laboratory Criterion for Rheumatoid Arthritis
    Scandinavian journal of rheumatology, 1993
    Co-Authors: R. Von Essen, Heikki Isomäki, Hannu Kautiainen, P T Kurki, S. Okubo, Kimmo Aho
    Abstract:

    The aim of the study was to establish the benefit of an additional hypothetical laboratory criterion for rheumatoid arthritis (RA), comprising positivity for antikeratin antibody (AKA) and/or Antiperinuclear Factor (APF). The tests were applied to a series of 308 hospital patients with various recent-onset inflammatory joint diseases who were followed for 3 years. The performance of APF and AKA was compared with rheumatoid Factor (RF). The most sensitive (.72) but the least specific (.86) test for RA was the latex test. The most specific (.96) but the least sensitive (.33) test was AKA. Waaler-Rose and APF were intermediate. AKA and/or APF positive patients had significantly more erosions than patients negative for these autoantibodies. Despite the impressive performance characteristics of APF and AKA, the actual classification impact achieved, as compared to using RF as the sole laboratory criterion, turned out to be moderate. This is because the criteria proved to be interrelated. Unlike RF, AKA and APF are not suited to the general laboratory, at least not in their present form. Moreover they so far lack the broad data base of RF.

A. Elias - One of the best experts on this subject based on the ideXlab platform.

  • British Journal of Rheumatology 1996;35:62O-624 DIAGNOSTIC VALUE OF ANTI-RA33 ANTIBODY, ANTTKERATIN ANTIBODY, ANTTPERINUCLEAR Factor AND ANTINUCLEAR ANTIBODY IN EARLY RHEUMATOID ARTHRITIS: COMPARISON WITH RHEUMATOID Factor
    2015
    Co-Authors: C. Cordonnier, O. Meyer, E. Palazzo, M. De Bandt, A. Elias, P. Nicaise, T. Halm, M. F. Kahn, G. Chatellier
    Abstract:

    The goal of this prospective longitudinal study was to determine the serological profile of early rheumatoid arthritis (RA), and to test whether antikeratin antibody (AKA), Antiperinuclear Factor (API7), anti-RA33 antibody and antinuclear antibodies (ANA) had an additional diagnostic value when prescribed after rheumatoid Factor (RF)-detecting methods. Sixty-nine patients with early polyarthritis suggestive of RA, seen between 1991 and 1993, were included. Five autoantibodies (i.e. RF, AKA, APF, RA33, ANA) were looked for at regular intervals. After 24 months follow-up, patients were classified as having RA (n = 49), unclassified polyarthritis (UP; n = 15) or other rheumatic diseases. Among patients with early RA, the sensitivity of these marker

  • Autoantibodies predicting the outcome of rheumatoid arthritis: evaluation in two subsets of patients according to severity of radiographic damage
    Annals of the rheumatic diseases, 1997
    Co-Authors: O. Meyer, A. Elias, Bernard Combe, K Benali, J Clot, Jacques Sany, Jean-françois Eliaou
    Abstract:

    OBJECTIVE Autoantibodies such as rheumatoid Factor (RF), antikeratin antibodies (AKA), Antiperinuclear Factor (APF), and anti-RA 33 antibodies are considered of value for the diagnosis of RA. The purpose of this study was to evaluate these autoantibodies as predictors of severe radiographic damage in rheumatoid arthritis (RA). PATIENTS AND METHODS Eighty six patients with RA (70 women, 16 men) fulfilling 1987 ACR criteria were selected from a cohort of 469 patients followed up since the first year of RA onset because they could be divided in two groups according to the severity of the radiographic damage. These 86 patients had a mean (SD) disease duration of eight (four) years: 43 patients had severe radiographic damage (Larsen score ⩾2) and 43 had limited radiographic damage (Larsen score RESULTS Patients with severe radiographic damage differed from those with limited radiographic damage in that they had higher RF (p=0.01), APF (p CONCLUSION These data suggest that the risk of severe radiographic damage in RA patients is higher when cutaneous nodules, HLA DRB1*04 or DRB1*01, and/or AKA are present. The other autoantibodies of diagnostic significance are of little help for predicting joint destruction.

  • DIAGNOSTIC VALUE OF ANTI-RA33 ANTIBODY, ANTIKERATIN ANTIBODY, Antiperinuclear Factor AND ANTINUCLEAR ANTIBODY IN EARLY RHEUMATOID ARTHRITIS: COMPARISON WITH RHEUMATOID Factor
    British journal of rheumatology, 1996
    Co-Authors: C. Cordonnier, O. Meyer, E. Palazzo, M. De Bandt, A. Elias, Nicaise P, T. Haim, G. Chatellier
    Abstract:

    The goal of this prospective longitudinal study was to determine the serological profile of early rheumatoid arthritis (RA), and to test whether antikeratin antibody (AKA), Antiperinuclear Factor (APF), anti-RA33 antibody and antinuclear antibodies (ANA) had an additional diagnostic value when prescribed after rheumatoid Factor (RF)-detecting methods. Sixty-nine patients with early polyarthritis suggestive of RA, seen between 1991 and 1993, were included. Five autoantibodies (i.e. RF, AKA, APF, RA33, ANA) were looked for at regular intervals. After 24 months follow-up, patients were classified as having RA (n = 49), unclassified polyarthritis (UP; n = 15) or other rheumatic diseases. Among patients with early RA, the sensitivity of these markers was 40.8% for RF, 36.7% for AKA, 28.6% for APF and 28.6% for anti-RA33. Among RF-negative RA patients, 51.7% were positive for AKA, APF, anti-RA33 antibodies and/or ANA. Positivity of the three recent markers usually persisted throughout follow-up, whereas RF was lost by 58% of patients with early, RF-positive, treated RA. Using multivariate analysis, only latex, RF test and AKA or APF had an independent and statistically significant diagnostic value for early RA. Our data suggest that RF and AKA (or APF) should be concomitantly determined for diagnosis in patients with suspected early RA.

  • Anti-RA 33 antinuclear autoantibody in rheumatoid arthritis and mixed connective tissue disease: comparison with antikeratin and Antiperinuclear antibodies
    Clinical and experimental rheumatology, 1993
    Co-Authors: Olivier Meyer, T. Haim, C Gabay, F Tauxe, D Fabregas, M. Goycochea, A. Elias
    Abstract:

    Besides rheumatoid Factor (RF), antikeratin antibodies (AKA) and Antiperinuclear Factor (APN), anti-RA 33 antibody has been described as a highly specific antinuclear antibody for rheumatoid arthritis (RA). In this study RA 33 antibodies were detected using Western blotting with HeLa cell nuclear extract in a group of 94 RA patients and 259 controls. Anti-RA 33 was present in 35% of 94 RA patients, with a similar frequency in RF positive (32%) and RF-negative (45%) RA patients. RA-33 antibody was also present in 60% of a group of 30 patients with anti-U1 RNP positive mixed connective tissue disease. The specificity of anti-RA 33 for RA was 84.6%. Anti-RA 33 antibody was already present in sera from 23.5% of 18 patients with RA of less than one year's duration. Anti-RA 33 antibody was the only positive immunological marker in 3/20 cases of seronegative adult RA. No correlations were found between anti-RA 33 antibody and AKA or APF. Patients with erosive RA and patients whose ESR was > or = 50 mm after 1 hour were more likely to be anti-RA 33 positive (47.6% vs 24.4% and 42.8% vs 29.4%). These results suggest that anti-RA 33 antibody, in the absence of anti-U1-RNP antibodies, can be added to the list of the helpful serological markers for rheumatoid arthritis.

Guy Serre - One of the best experts on this subject based on the ideXlab platform.

  • Autoanticorps anti-protéines “citrullinées” dans la polyarthrite rhumatoïde
    BioTribune Magazine, 2003
    Co-Authors: Christian Vincent, Mireille Sebbag, Leonore Nogueira, Sabine Chapuy-regaud, Cyril Clavel, Nathalie Moinard, Guy Serre
    Abstract:

    En 1964, RLF Nienhuis et coll. [1] décrivaient, dans plus de deux tiers des sérums de patients atteints de polyarthrite rhumatoïde (PR), des anticorps marquant en immunofluorescence indirecte des granules périnucléaires présents dans les cellules les plus superficielles de la muqueuse jugale humaine. Ces anticorps étaient appelés “facteur anti-périnucléaire” (Antiperinuclear Factor: APF) par analogie avec le “facteur” rhumatoïde (FR) qui constituait alors l’unique marqueur biologique de la PR. Quinze ans plus tard, une équipe anglaise, BJJ Young et coll. [2] montrait qu’environ la moitié des patients atteints de PR présentait des anticorps circulants marquant en immunofluorescence indirecte la couche cornée de l’épithélium malpighien qui revêt l’œsophage de rat. Les kératines étant les protéines les plus abondantes et les mieux connues dans cette couche épithéliale, les auteurs appelaient ces anticorps “anti-kératine” (antikeratin antibodies: AKA), en l’absence de tout élément biochimique permettant d’affirmer la nature de l’antigène reconnu.

  • anti perinuclear Factor compared with the so called antikeratin antibodies and antibodies to human epidermis filaggrin in the diagnosis of arthritides
    Annals of the Rheumatic Diseases, 1999
    Co-Authors: Christian Vincent, F De Keyser, E. M. Veys, Mireille Sebbag, C Massonbessiere, Guy Serre
    Abstract:

    OBJECTIVE—Antiperinuclear Factor (APF), "antikeratin antibodies" ("AKA"), and antibodies to human epidermis filaggrin (AFA), are highly specific serological markers of rheumatoid arthritis (RA), which recognise epitopes on various isoforms of (pro)filaggrin. It was proposed that these antibodies are globally named antifilaggrin autoantibodies. Here the diagnostic value of the detection of each one is compared and the overlap between the three tests evaluated. METHODS—492 serum samples were tested, including 279 RA serum samples, taken from patients in France and Belgium. APF and "AKA" titres were estimated by indirect immunofluorescence, and AFA titres by immunoblotting on filaggrin enriched human epidermis extracts. RESULTS—By a convenient choice of the positivity thresholds, the diagnostic sensitivity and specificity of the tests were shown to be similar (0.52 and 0.97, respectively). Although the antibody titres were strongly correlated, the associations APF-AFA or AFA-"AKA" permitted more than 52% or 55% of RA to be diagnosed, with a specificity of 0.99. CONCLUSION—APF, "AKA", and AFA detection have a similar diagnostic value. However, because the three tests do not totally overlap, associating APF with "AKA" or AFA with "AKA" can improve diagnostic sensitivity. None of the three antigens used bear all the epitopes recognised by anti-filaggrin autoantibodies. Keywords: rheumatoid arthritis; antifilaggrin autoantibodies; Antiperinuclear Factor; antikeratin antibodies

  • immunoblotting detection of autoantibodies to human epidermis filaggrin a new diagnostic test for rheumatoid arthritis
    The Journal of Rheumatology, 1998
    Co-Authors: Christian Vincent, Mireille Sebbag, Michel Simon, Jeanjacques Durieux, Elisabeth Girbalneuhauser, A Cantagrel, B Fournie, B Mazieres, Guy Serre
    Abstract:

    Objective. We previously reported that so-called antikeratin antibodies (AKA) and Antiperinuclear Factor (APF) recognize epitope(s) present on human epidermal filaggrin. In the present study, we developed a new diagnostic test for rheumatoid arthritis (RA) based on detection of antifilaggrin autoantibodies (AFA) by immunoblotting. Methods. We tested 670 serum samples, including 190 RA. AFA titers were estimated by immunoblotting on filaggrin enriched human epidermis extracts, and AKA titers by indirect immunofluorescence (IIF) on rat esophagus epithelium. Diagnostic values of the tests were compared. Results. Each test resulted in diagnosis of more than 40% of RA samples, with a specificity of 0.99. Although the tests were strongly correlated, their association allowed the diagnosis of more than 60% of RA samples, with the same specificity. Conclusion. Immunoblot detection of AFA, a simple and standardizable test, may be an alternative or complement to conventional IIF detection of AKA.

  • Normal human epidermal keratinocytes express in vitro specific molecular forms of (pro)filaggrin recognized by rheumatoid arthritis-associated antifilaggrin autoantibodies.
    Molecular medicine (Cambridge Mass.), 1997
    Co-Authors: Elisabeth Girbal-neuhauser, Mireille Sebbag, Michel Simon, Jeanjacques Durieux, Martine Montézin, Françoise Croute, Guy Serre
    Abstract:

    Background The so-called antikeratin antibodies and the Antiperinuclear Factor are the most specific serological markers of rheumatoid arthritis (RA). They were recently shown to be largely the same autoantibodies and to recognize human epidermal filaggrins and profilaggrin-related proteins of buccal epithelial cells (collectively referred to as (pro)filaggrin).

  • Filaggrin (Keratin) Autoantibodies
    Autoantibodies, 1996
    Co-Authors: Guy Serre, Christian Vincent
    Abstract:

    Publisher Summary This chapter gives a striking account of antikeratin antibodies (AKA). These autoantibodies that are present in about one third of rheumatoid Factor (RF)-negative rheumatoid arthritis (RA), are linked with the biological and clinical parameters that define the more active and severe forms of the disease. AKA and Antiperinuclear Factor (APF), another diagnostic marker of RA, were shown to be the same autoantibodies that recognize human epidermal filaggrin and (pro) filaggrin-related proteins of buccal epithelial cells. AKA are also potential prognostic markers. The presence and the titer of AKA are related to several serological indices of disease activity and severity such as erythrocyte sedimentation rate, increased levels of C-reactive protein RF, or soluble immune complexes. Their association with functional indexes and subcutaneous nodules suggests that the presence of AKA defines more severe forms of RA.